Company News

Biofidelity announces first peer reviewed publication of breakthrough ASPYRE technology

Biofidelity Ltd, the cancer diagnostics company, today announces that the first peer review article detailing its novel ASPYRE technology has been published in Scientific Reports, a Nature journal.  The article, titled “Single-copy detection of somatic variants from solid and liquid biopsy” is freely available online at www.nature.com/articles/s41598-021-85545-3. As well as detailing the novel technology behind ASPYRE, the publication evidences the flexibility of Biofidelity’s breakthrough approach, through its application to the detection of a variety of key genetic mutations used to guide treatment decisions in lung cancer. Read more

Related stories

Read More

Tucked inside the Trinity Centre is one of the Park’s most unexpected high-performance environments: a Brazilian Jiu-Jitsu academy run by Leo ...

Read More

Cambridge Science Centre, based at the Park’s Trinity Centre, has unveiled a bold new five-year strategy designed to help secure ...

Read More

Billy Boyle, founder and CEO of Owlstone Medical, is turning endurance into action and inviting others to join him and ...

Want to see your news featured here? Contact the team and let’s spread the word.